Search results
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 5 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 5 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Why Earnings Season Could Be Great for Moderna (MRNA)
Zacks via Yahoo Finance· 6 days agoInvestors are always looking for stocks that are poised to beat at earnings season and Moderna, Inc....
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 5 days agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna (MRNA) Set to Announce Earnings on Thursday
ETF DAILY NEWS· 6 days agoModerna (NASDAQ:MRNA – Get Free Report) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Moderna to post ...
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight
FierceBiotech· 6 days agoEarlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks. Back in 2021 ...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 5 days agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 5 days agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
Guru Focus· 3 days agoOn May 2, 2024, Moderna Inc (MRNA, Financial) filed its 10-Q report, revealing a challenging quarter with a stark decrease in revenue and a shift from profitability to a net ...
Why Earnings Season Could Be Great for Moderna (MRNA)
Zacks· 6 days agoFree Report) may be one such company. In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $3.55 per share for MRNA, narrower than the broader Zacks Consensus ...